Sign In
Buy MDGL
$512.88
+7.13 (+1.41%)
At Close: Jun 22, 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 21'st Oct 2025
CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal Pharma CEO talks competition in the liver disease treatment space
06:18pm, Thursday, 16'th Oct 2025
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk how Rezdiffra stacks up to competitors in the MASH treatment space, sales growth for the drug over the last year, and more.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 07'th Oct 2025
CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising
07:30am, Tuesday, 30'th Sep 2025
MDGL's Rezdiffra is its main value driver. This is the first FDA-approved MASH F2–F3 therapy. So far, Rezdiffra shows a rapid U.S. uptake and market penetration. Management projects over 23,000 pati
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 18'th Sep 2025
CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
10:27am, Monday, 08'th Sep 2025
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants William Sibold - CEO, President & Director Davi
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 04'th Sep 2025
CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
08:00am, Wednesday, 03'rd Sep 2025
CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Health Ca
Biopharma and Energy Execs Lead Weekly Insider Buying
08:45am, Thursday, 28'th Aug 2025
Among the past week's most notable insider buying, a biopharmaceutical company that recently received approval for its primary treatment had a director scooping up shares.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st Aug 2025
CONSHOHOCKEN, Pa., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
01:45pm, Wednesday, 20'th Aug 2025
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further
04:04pm, Friday, 15'th Aug 2025
Rezdiffra's Q2 '25 net sales surged 55% to $212.8M, beating expectations and highlighting strong commercial momentum for Madrigal Pharmaceuticals, Inc. Despite robust revenue growth, Madrigal Pharmace
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
08:00am, Monday, 11'th Aug 2025
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Confere
Madrigal Pharmaceuticals CEO: We're positioned for decades of growth
06:15pm, Friday, 08'th Aug 2025
Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their GLP-1 strategy.
